Set targets, assess response, intervene early to achieve minimal disease activity in atopic dermatitis (STRIVE AD): A modified Delphi consensus project to optimize management of atopic dermatitis in the United Kingdom
Year: 2025
Type: article
Abstract: Background: Guidelines for the management and treatment of atopic dermatitis have been extensively published in Europe and globally, however these are not always relevant to the United Kingdom (UK) clinical setting. Objectives: To develop consensus statements for the optimized management of adults and children with atopic dermatitis in the UK. Method: Consensus statements were developed by an expert advisory panel following a targeted literature review, based on 5 topics (patient centric approach, assessing severity consistently, setting treatment targets, early intervention, and optimizing treatment). Consensus statements were voted on using a 5-point Likert scale in a Delphi over 3 rounds by 12 multidisciplinary, geographically spread participants. Consensus was reached if ≥75% of the voting participants rated the statement as 4 or 5. Results: Strong consensus (≥90%) was achieved for 24 out of 27 statements. The level of consensus by topic was: Patient centric approach (92%-100%); Assessing severity consistently (75%-100%); Setting treatment targets (83%-100%); Intervening early (92%-100%); Optimizing treatment (92%). Limitations: Due to the design and objectives of the study only a small number of participants were invited to take part. Conclusions: The following recommendations have been developed to be practical and easy to implement within everyday clinical practice.
Source: JAAD International
Institutions: Barts Health NHS Trust, King's College London, Guy's and St Thomas' NHS Foundation Trust, Gloucestershire Hospitals NHS Foundation Trust, Kingston Hospital, NHS Greater Glasgow and Clyde, Salford Royal NHS Foundation Trust, National Eczema Society, NHS Fife, University of Leeds, Leeds Teaching Hospitals NHS Trust
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,575
Funder: AbbVie
OpenAlex ID: W4417443622
